Oct 28, 2016
A key hallmark of many of the most exceptional deals that the Locust Walk team have done involves having successfully developed the marketplace in advance of and leading up to a significant corporate milestone. As advisors, we are often able to more rapidly engage...
Sep 21, 2016
While they sound similar, “stock” vs. “asset” purchase agreements are very different in nature and have meaningful implications for company management, boards and investors. At Locust Walk, we work with myriad small, single-product companies that are looking for help...
Sep 8, 2016
Article appearing in “The Huffington Post” about Geoff Meyerson, Managing Partner and Co-Founder and Locust Walk business. Convergence is when several people or things come together from different directions so as to eventually meet. Way up on the 18th...
Sep 8, 2016
When a deal process is begun, the initial focus is on identifying good potential partners and getting them engaged in preliminary discussions. As one or more potential partners advance beyond these early discussions, the process moves into the critical due diligence...
Jul 25, 2016
Many Japanese pharmaceutical companies are now “global” in terms of scope and size. Companies like Takeda, Astellas, and Daiichi Sankyo have established their commercial footprint around the world. Accordingly, the business development teams at these companies are...
Jul 7, 2016
Licensing and M&A deals are an essential part of the success, lifeblood and motivation for small biopharmaceutical companies. As large and specialty pharmaceutical and biotech companies continually strive for innovation, there are powerful financial incentives...
